Mayo Clinic Proceedings Home

Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines


      The 2013 American College of Cardiology/American Heart Association cardiovascular disease prevention guidelines represent an important step forward in the risk assessment and management of atherosclerotic cardiovascular disease in clinical practice. Differentiated risk prediction equations for women and black individuals were developed, and convenient 10-year and lifetime risk assessment tools were provided, facilitating their implementation. Lifestyle modification was portrayed as the foundation of preventive therapy. In addition, based on high-quality evidence from randomized controlled trials, statins were prioritized as the first lipid-lowering pharmacologic treatment, and a shared decision-making model between the physician and the patient was emphasized as a key feature of personalized care. After publication of the guidelines, however, important limitations were also identified. This resulted in a constructive scientific debate yielding valuable insights into potential opportunities to refine recommendations, fill gaps in guidance, and better harmonize recommendations within and outside the United States. The latter point deserves emphasis because when guidelines are in disagreement, this may result in nonaction on the part of professional caregivers or nonadherence by patients. In this review, we discuss the key scientific literature relevant to the guidelines published in the year and a half after their release. We aim to provide cohesive, evidence-based views that may offer pathways forward in cardiovascular disease prevention toward greater consensus and benefit the practice of clinical medicine.

      Abbreviations and Acronyms:

      ACC/AHA ( American College of Cardiology/American Heart Association), ASCVD ( atherosclerotic cardiovascular disease), ATP III ( Adult Treatment Panel III), CAC ( coronary artery calcium), CHD ( coronary heart disease), CVD ( cardiovascular disease), DM ( diabetes mellitus), FRS ( Framingham Risk Score), IMPROVE-IT ( Improved Reduction of Outcomes: Vytorin Efficacy International Trial), LDL-C ( low-density lipoprotein cholesterol), MESA ( Multi-Ethnic Study of Atherosclerosis), NHANES ( National Health and Nutrition Examination Survey), PHS ( Physicians’ Health Study), REGARDS ( Reasons for Geographic and Racial Differences in Stroke), WHI-OS ( Women’s Health Initiative Observational Study), WHS ( Women’s Health Study)


        • Goff Jr., D.C.
        • Lloyd-Jones D.M.
        • Bennett G.
        • et al.
        2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2935-2959
        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • et al.
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2889-2934
        • Eckel R.H.
        • Jakicic J.M.
        • Ard J.D.
        • et al.
        2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2960-2984
        • Jensen M.D.
        • Ryan D.H.
        • Apovian C.M.
        • et al.
        2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.
        J Am Coll Cardiol. 2014; 63: 2985-3023
        • Ridker P.M.
        • Cook N.R.
        Statins: new American guidelines for prevention of cardiovascular disease.
        Lancet. 2013; 382: 1762-1765
        • Amin N.P.
        • Martin S.S.
        • Blaha M.J.
        • Nasir K.
        • Blumenthal R.S.
        • Michos E.D.
        Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines.
        J Am Coll Cardiol. 2014; 63: 2789-2794
        • Martin S.S.
        • Abd T.T.
        • Jones S.R.
        • Michos E.D.
        • Blumenthal R.S.
        • Blaha M.J.
        2013 ACC/AHA cholesterol treatment guideline: what was done well and what could be done better.
        J Am Coll Cardiol. 2014; 63: 2674-2678
        • Kullo I.J.
        • Trejo-Gutierrez J.F.
        • Lopez-Jimenez F.
        • et al.
        A perspective on the New American College of Cardiology/American Heart Association guidelines for cardiovascular risk assessment.
        Mayo Clin Proc. 2014; 89: 1244-1256
        • Lopez-Jimenez F.
        • Simha V.
        • Thomas R.J.
        • et al.
        A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps.
        Mayo Clin Proc. 2014; 89: 1257-1278
        • Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel Members
        An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia: full report.
        J Clin Lipidol. 2014; 8: 29-60
        • Perk J.
        • De Backer G.
        • Gohlke H.
        • et al.
        European Guidelines on cardiovascular disease prevention in clinical practice (version 2012).
        Eur Heart J. 2012; 33: 1635-1701
        • Anderson T.J.
        • Grégoire J.
        • Hegele R.A.
        • et al.
        2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.
        Can J Cardiol. 2013; 29: 151-167
        • Blaha M.J.
        • Blumenthal R.S.
        Risk factors: new risk-assessment guidelines-more or less personalized?.
        Nat Rev Cardiol. 2014; 11: 136-137
        • Akosah K.O.
        • Schaper A.
        • Cogbill C.
        • Schoenfeld P.
        Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform?.
        J Am Coll Cardiol. 2003; 41: 1475-1479
        • Michos E.D.
        • Nasir K.
        • Braunstein J.B.
        • et al.
        Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women.
        Atherosclerosis. 2006; 184: 201-206
        • Pencina M.J.
        • Navar-Boggan A.M.
        • D'Agostino Sr., R.B.
        • et al.
        Application of new cholesterol guidelines to a population-based sample.
        N Engl J Med. 2014; 370: 1422-1431
        • Muntner P.
        • Colantonio L.D.
        • Cushman M.
        • et al.
        Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations.
        JAMA. 2014; 311: 1406-1415
        • Cook N.R.
        • Ridker P.M.
        Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study.
        JAMA Intern Med. 2014; 174: 1964-1971
        • DeFilippis A.P.
        • Young R.
        • Carrubba C.J.
        • et al.
        An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort.
        Ann Intern Med. 2015; 162: 266-275
        • Silverman M.G.
        • Blaha M.J.
        • Krumholz H.M.
        • et al.
        Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis.
        Eur Heart J. 2014; 35: 2232-2241
        • Martin S.S.
        • Blaha M.J.
        • Blankstein R.
        • et al.
        Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.
        Circulation. 2014; 129: 77-86
        • Goff D.C.
        • Lloyd-Jones D.M.
        • Bennett G.
        • et al.
        2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2014; 129: S49-S73
        • Miedema M.D.
        • Lopez F.L.
        • Blaha M.J.
        • et al.
        Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US cohort: the Atherosclerosis Risk in Communities Study cohort.
        JAMA Intern Med. 2015; 175: 138-140
        • Johnson K.M.
        • Dowe D.A.
        Accuracy of statin assignment using the 2013 AHA/ACC Cholesterol Guideline versus the 2001 NCEP ATP III guideline: correlation with atherosclerotic plaque imaging.
        J Am Coll Cardiol. 2014; 64: 910-919
        • Pursnani A.
        • Mayrhofer T.
        • Ferencik M.
        • Hoffmann U.
        The 2013 ACC/AHA cardiovascular prevention guidelines improve alignment of statin therapy with coronary atherosclerosis as detected by coronary computed tomography angiography.
        Atherosclerosis. 2014; 237: 314-318
        • McEvoy J.W.
        • Diamond G.A.
        • Detrano R.C.
        • et al.
        Risk and the physics of clinical prediction.
        Am J Cardiol. 2014; 113: 1429-1435
      1. US Census Bureau. Hispanic population of the United States: 1970-2050. Accessed July 18, 2015.

      2. US Census Bureau. Census 2000: Chinese largest Asian group in the United States. Accessed July 18, 2015.

        • Cortes-Bergoderi M.
        • Goel K.
        • Murad M.H.
        • et al.
        Cardiovascular mortality in Hispanics compared to non-Hispanic whites: a systematic review and meta-analysis of the Hispanic paradox.
        Eur J Intern Med. 2013; 24: 791-799
        • Anand S.S.
        • Yusuf S.
        • Vuksan V.
        • et al.
        Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE).
        Lancet. 2000; 356: 279-284
        • Martin S.S.
        • Sperling L.S.
        • Blaha M.J.
        • et al.
        Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA guidelines.
        J Am Coll Cardiol. 2015; 65: 1361-1368
        • Detrano R.
        • Guerci A.D.
        • Carr J.J.
        • et al.
        Coronary calcium as a predictor of coronary events in four racial or ethnic groups.
        N Engl J Med. 2008; 358: 1336-1345
        • Yeboah J.
        • McClelland R.L.
        • Polonsky T.S.
        • et al.
        Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.
        JAMA. 2012; 308: 788-795
        • Kavousi M.
        • Elias-Smale S.
        • Rutten J.H.
        • et al.
        Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study.
        Ann Intern Med. 2012; 156: 438-444
        • Rana J.S.
        • Gransar H.
        • Wong N.D.
        • et al.
        Comparative value of coronary artery calcium and multiple blood biomarkers for prognostication of cardiovascular events.
        Am J Cardiol. 2012; 109: 1449-1453
        • Erbel R.
        • Möhlenkamp S.
        • Moebus S.
        • et al.
        Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study.
        J Am Coll Cardiol. 2010; 56: 1397-1406
        • Peters S.A.E.
        • den Ruijter H.M.
        • Bots M.L.
        • Moons K.G.
        Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review.
        Heart. 2012; 98: 177-184
        • Tota-Maharaj R.
        • Blaha M.J.
        • Blankstein R.
        • et al.
        Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort.
        Mayo Clin Proc. 2014; 89: 1350-1359
        • Sarwar A.
        • Shaw L.J.
        • Shapiro M.D.
        • et al.
        Diagnostic and prognostic value of absence of coronary artery calcification.
        JACC Cardiovasc Imaging. 2009; 2: 675-688
        • Pletcher M.J.
        • Pignone M.
        • Earnshaw S.
        • et al.
        Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.
        Circ Cardiovasc Qual Outcomes. 2014; 7: 276-284
        • Miedema M.D.
        • Duprez D.A.
        • Misialek J.R.
        • et al.
        Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis.
        Circ Cardiovasc Qual Outcomes. 2014; 7: 453-460
        • Bittencourt M.S.
        • Blaha M.J.
        • Blankstein R.
        • et al.
        Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis).
        J Am Coll Cardiol. 2014; 63: 434-443
        • Nakanishi R.
        • Li D.
        • Blaha M.J.
        • et al.
        The relationship between coronary artery calcium score and the long-term mortality among patients with minimal or absent coronary artery risk factors.
        Int J Cardiol. 2015; 185: 275-281
        • Blaha M.J.
        • Dardari Z.A.
        • Blumenthal R.S.
        • Martin S.S.
        • Nasir K.
        • Al-Mallah M.H.
        The new “intermediate risk” group: a comparative analysis of the new 2013 ACC/AHA risk assessment guidelines versus prior guidelines in men.
        Atherosclerosis. 2014; 237: 1-4
        • Martin S.S.
        • Blumenthal R.S.
        Concepts and controversies: the 2013 American College of Cardiology/American Heart Association risk assessment and cholesterol treatment guidelines.
        Ann Intern Med. 2014; 160: 356-358
        • Yousuf O.
        • Mohanty B.D.
        • Martin S.S.
        • et al.
        High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?.
        J Am Coll Cardiol. 2013; 62: 397-408
        • Bower J.K.
        • Lazo M.
        • Juraschek S.P.
        • Selvin E.
        Within-person variability in high-sensitivity C-reactive protein.
        Arch Intern Med. 2012; 172: 1519-1521
        • Lin J.S.
        • Olson C.M.
        • Johnson E.S.
        • Whitlock E.P.
        The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force.
        Ann Intern Med. 2013; 159: 333-341
        • Stein J.H.
        • Korcarz C.E.
        • Hurst R.T.
        • et al.
        Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force: endorsed by the Society for Vascular Medicine.
        J Am Soc Echocardiogr. 2008; 21: 93-111
        • Erbel R.
        • Budoff M.
        Improvement of cardiovascular risk prediction using coronary imaging: subclinical atherosclerosis: the memory of lifetime risk factor exposure.
        Eur Heart J. 2012; 33: 1201-1213
        • Berry J.D.
        • Liu K.
        • Folsom A.R.
        • et al.
        Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis.
        Circulation. 2009; 119: 382-389
        • Wu L.
        • Parhofer K.G.
        Diabetic dyslipidemia.
        Metabolism. 2014; 63: 1469-1479
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • et al.
        Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
        N Engl J Med. 2015; 372: 2387-2397
        • Jacobson T.A.
        • Ito M.K.
        • Maki K.C.
        • Orringer C.E.
        • Bays H.E.
        • Jones P.H.
        National Lipid Association recommendations for patient-centered management of dyslipidemia, part 1: executive summary.
        J Clin Lipidol. 2014; 8: 473-488
        • Oshima Lee E.
        • Emanuel E.J.
        Shared decision making to improve care and reduce costs.
        N Engl J Med. 2013; 368: 6-8